Expert Recommendation: Contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD)

Actas Espanolas de Psiquiatria

Volumn 42, Issue , 2014, Pages 1-16

  Alda, José A ^a   Soutullo, César ^b   Ramos Quiroga, Josep A ^c   Quintero, Javier ^d   Hervás, Amaia ^a   Hernández Otero, Isabel ^e   Sans Fitó, Anna ^a   Cardo Jalón, Esther ^f   Fernández Jaén, Alberto ^g   Fernández Pérez, Maximino ^h   Hidalgo Vieario, Ma Inés ⁱ   Eddy Ives, Lefa S ^j   Sánchez, Javier ^k  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e Unidad de Salud Mental Infanto Juvenil   (Spain)

^f UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^g Hospital Universitario Quiron   (Spain)

^h Centra de Salud de La Eelguera   (Spain)

ⁱ SERMAS   (Spain)

^j Centre Mèdic Sant Ramon   (Spain)

^k AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

more..

Author keywords

ADHD; Dimesylate; LDX; Lisdexamfetamine

Indexed keywords

DOPAMINE UPTAKE INHIBITOR; LISDEXAMFETAMINE; PRODRUG;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMAN; PRACTICE GUIDELINE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINE UPTAKE INHIBITORS; HUMANS; LISDEXAMFETAMINE DIMESYLATE; PRODRUGS;

EID: 84924353049     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Sanchez CR, Ramos C, Diaz F, Lopez D. Attention-deficit/hyperactivity disorder: prevalence of risk in the scholastic scope of the Canary Islands. Actas Esp Psiquiatr. 2014 Jul- Aug;42(4):169-75.
2. Quintero J, Balanza-Martinez V, Correas J, Soler B; Grupo Geda-A. Attention Deficit Hyperactivity Disorder (ADHD) in the adult patients: view of the clinician. Actas Esp Psiquiatr. 2013 May-Jun;41(3):185-95.
3. Keyes KM, Susser E, Pilowsky DJ, Hamilton A, Bitfoi A, Goelitz D, et al. The health consequences of child mental health problems and parenting styles: Unintentional injuries among European schoolchildren. Prev Med. 2014 Oct;67:182-8.
4. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-48.
5. Pelham WE, Gnagy EM, GreinerAR, Hoza B, Hinshaw SP, Swanson JM, et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol. 2000 Dec;28(6):507-25.
6. Grupo de trabajo de la Guia de Practica Clinica sobre el Trastorno por Deficit de Atencion con Hiperactividad (TDAH) en Ninos y Adolescentes. Fundacio Sant Joan de Deu, coordinador. Guia de Practica Clinica sobre el Trastorno por Deficit de Atencion con Hiperactividad (TDAH) en Ninos y Adolescentes. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Poli'tica Social e Igualdad. Agenda d'lnformacio, Avaluacio i Qualitat (AIAQS) de Cataluna; 2010. Guias de Practica Clinica en el SNS: AATRM N° 2007/18.
7. Hodgkins P, Setyawan J, Mitra D, Davis K, Quintero J, Fridman M, et al. Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns. Eur J Pediatr. Jul 2013;172(7): 895-906.
8. Seixas M, Wiess M, Muller U. Systematic review of national and international guideline on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012 Jun;26(6):753-65.
9. Faraone SV. Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. PT. 2009 Dec;34(12):678-94.
10. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using metaanalysis of effect sizes. J Clin Psychiatry. 2010 Jun;71(6):754-63.
11. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol. 2006 Jun;16(3):286-97.
12. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009a;23(4):419- 27.
13. Human pharmacology of intravenous lisdexamfetamine dimesylate: Abuse, liability in adult stimulant abusers. J Psychopharmacol. 2009b;23(4):410-8.
14. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: Epidemiology, prevention and management. CNS Drugs. 2008;22(3):213-37.
15. Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007; 62(9): 954-62.
16. Efron D, Jarman F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics. 1997;100(6):E6.
17. Margaret Steele, Peter S Jensen, Declan MP Quinn. Remission Versus Response as the Goal of Therapy in ADHD: A New Standard for the Field? Clinical Therapeutics. 2006;28(11):1892- 908.
18. Ramos JA, Casas M. Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder. CNS Drugs. 2011;25(1):17-36.
19. Jeffery N. Epstein, Margaret D. Weiss. Assessing Treatment Outcomes in Attention-Deficit/Hyperactivity Disorder: A Narrative Review. Prim Care Companion CNS Disord. 2012;14(6): PCC.1101336.;.
20. Biederman J, Seidman U, Petty CR, Fried R, Doyle AE, Cohen DR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Jul;69(7):1150-6.
21. Childress AC, Sallee FR. The use of lisdexamfetamine dimesylate for the treatment of ADHD. Expert Rev Neurother. 2012 Jan;12(1):13-26.
22. Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch B. Lisdexamfetamine dimesylate: linear dose- proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol. 2010 Sep;50(9):1001-10.
23. Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013 0ct;23(10):1208-18.
24. Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014 Jun;53(6):647-57.
25. Biederman J, Krishnan S, Zhang Y, James J. McGough JJ, Findling RL Efficacy and Tolerability of Lisdexamfetamine Dimesylate (NRP-104) in Children with Attention Deficit/Hyperactivity Disorder: A Phase III, Multicenter, Randomized, Double-Blind, Forced-Dose, Parallel-Group Study. Clinical Therapeutics. March 2007;29(3):450-63.
26. Robert L Findling, Ann C Childress, Andrew J Cutler, Maria Gasior, Mohamed Hamdani, Celeste Ferrerira-Cornwell, et al. Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder. JAACAP. April 2011;50(4):395-405.
27. Adler LA, Goodman DW, KollinsSH, Weisler RH, Krishnan S, Zhang Y, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Sep;69(9):1364-73.
28. Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira- Cornwell MC, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013 Feb;23(1):11-21.
29. Ginsberg L, Katie A, Adeyi B, Dirks B, Babcock T, Lasser R, et al. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Curr Med Res Opin. 2011 Jun;27(6):1097-107.
30. Coghill DR, Banaschewski T, Lecendreux M, Zuddas A, Dittmann RW, Otero IH, et al. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention- deficit/hyperactivity disorder: results from a randomized, controlled trial. Eur Child Adolesc Psychiatry. 2014 Feb;23(2):61-8.
31. Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder CNS Drugs. 2013;27(10):829-40.
32. Liza A Squires, Tobias Banaschewski, Michel Lecendreux, Mats Johnson, Alessandro Zuddas, Paul Hodgkins, et al. Health-related quality of life and functional outcomes from a randomized- Withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. Presented at the 59th AACAP Annual Meeting, 23-28 October 2012, San Francisco, CA, USA.
33. Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, et al. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs. 2013 Sep;27(9):743-51.
34. Alda Diez JA, Hernandez Otero I, Soutullo C, Civil R, Bloomfield R, Squires LA, et al. Eficacia del dimesilato de lidexanfetamina en ninos y adolescentes con trastornos por deficit de atencion e hiperactividad: Efecto de la edad, el sexo y la intensidad de la enfermedad en la linea base. 58 Congreso de la Asociacion Espanola de Psiquiatria del Nino y del Adolescente (AEPNYA). Granada, 16-18 Mayo 2013.
35. Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: A post hoc analysis. Child Adolesc Psychiatry Ment Health. 2011 Nov 4;5(1):35.
36. Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: A head-to-head, randomized, double-blind, phase lllb study. CNS Drugs. 2013 Dec;27(12):1081-92.
37. Juliana Setyawan, Paul Hodgkins, Annie Guerin, Genevieve Gauthier, Martin Cloutier, Eric O. Wu, et al. Comparing Treatment Adherence of Lisdexamfetamine and Other Medications for the Treatment of Attention Deficit/Hyperactivity Disorder: A Retrospective Analysis. J Med Econ.July 2013;16(7):962-75.
38. Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims- based analysis of a managed care population. Curr Med Res Opin. 2010;26(4):977-89.
39. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008 JuI; 13(7):614-20.
40. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007 Nov 1;62(9):970-6.
41. Spiller HA, Spyker DA, Casavant MJ. Comparison of US population and live birth rates with poison exposures reported to the National Poison Data System (NPDS): children ages 0-5 years from 2000 to 2012. Clin Toxicol (Phila). 2013 Mar;51(3):151-5.
42. Brahm NC, Hamilton DR. Alopecia following initiation of lisdexamfetamine in a pediatric patient. Prim Care Companion J Clin Psychiatry. 2009;11(6):365.
43. Hood B, Nowicki MJ. Eosinophilic hepatitis in an adolescent during lisdexamfetamine dimesylate treatment for ADHD. Pediatrics. 2010 Jun; 125(6):e 1510-3.
44. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: A randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatry Res. 2012 Apr;46(4):484-91.
45. Goodman D, Scheckner B, Dirks B, BabcockT, Adeyi B, Lasser R, et al. Safety profile of Lisdexamfetamine Dimesylate in Short-Term Clinical Trials in Children, Adolescents and Adults with ADHD. Poster presentation at American Psychiatric Association 163rd annual meeting; May 22-25, 2010; New Orleans, LA. 2010.
46. Chang Z, Lichtenstein P, Halldner L, D'Onofrio B, Serlachius E, Fazel S, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014 Aug;55(8):878-85.
47. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: A meta-analysis. JAMA Psychiatry. 2013;70:740-9.
48. National Institute for Health and Clinical Excellence. Diagnosis and management of ADHD in children, young people and adults. London: National Clinical Practice Guideline Number 72; 2009. http://www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf. Accessed 18 June 2013.
49. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry, 2003;160(11): 1909-18.
50. Ermer JC, Dennis K, Haffey MB, Doll WJ, Sandefer EP, Buckwalter M, et al. Intranasal versus oral administration of lisdexamfetamine dimesylate: A randomized, open-label, two- period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig. 2011;31(6):357- 70.
51. Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014 Jun;28(6):497-511.
52. Sembower MA, Ertischek MD, Buchholtz C, Dasgupta N, Schnoll SH. Surveillance of diversion and nonmedical use of extended- release prescription amphetamine and oral methylphenidate in the United States. J Addict Dis. 2013: 32(1):26-3.